CTLA4 and melanoma: Hence, CTLA-4 humanized monoclonal antibodies (mAB) such as ipilimumab and tremelimumab have demonstrated great clinical benefits in many different malignancies, including melanoma, lung carcinoma, and renal cell carcinoma, but not in BC [20, 36, 116].